Taysha Gene Therapies (TSHA) Misses Q1 EPS by 24c

Taysha Gene Therapies (NASDAQ: TSHA) reported Q1 EPS of ($1.31), $0.24 worse than the analyst estimate of ($1.07).

For earnings history and earnings-related data on Taysha Gene Therapies (TSHA) click here.

You May Also Be Interested In

• EU proposes to curb Airbnb and short-term rentals amid housing shortage
• Lynx Equity sees Micron and SanDisk breakout as volatility normalizes
• Concurrent Technologies (CNC:LN) PT Raised to GBP3.20 at Berenberg